Tackling Ethical Challenges of Premature Delivery of Stem Cell-Based Therapies: ISSCR 2018 Annual Meeting Focus Session Report

Jeremy Sugarman, Roger A. Barker, Ian Kerridge, Tamra Lysaght, Graziella Pellegrini, Douglas Sipp, Claire Tanner

Research output: Contribution to journalArticle

Abstract

Clinical uses of unproven stem cell-based interventions abound, yet many patients may be harmed by receiving them, raising complex ethical, economic, and societal concerns. Regulators, scientists, clinicians, professional societies, and patient advocacy groups need to collaboratively articulate expectations related to the proper development and delivery of stem cell-based therapies. Clinical uses of unproven stem cell-based interventions abound, yet many patients may be harmed by receiving them, raising complex ethical, economic, and societal concerns. Regulators, scientists, clinicians, professional societies, and patient advocacy groups need to collaboratively articulate expectations related to the proper development and delivery of stem cell-based therapies.

Original languageEnglish (US)
Pages (from-to)1021-1025
Number of pages5
JournalStem Cell Reports
Volume11
Issue number5
DOIs
StatePublished - Nov 13 2018

Fingerprint

Cell- and Tissue-Based Therapy
Stem cells
Stem Cells
Patient Advocacy
Economics

ASJC Scopus subject areas

  • Biochemistry
  • Genetics
  • Developmental Biology
  • Cell Biology

Cite this

Tackling Ethical Challenges of Premature Delivery of Stem Cell-Based Therapies : ISSCR 2018 Annual Meeting Focus Session Report. / Sugarman, Jeremy; Barker, Roger A.; Kerridge, Ian; Lysaght, Tamra; Pellegrini, Graziella; Sipp, Douglas; Tanner, Claire.

In: Stem Cell Reports, Vol. 11, No. 5, 13.11.2018, p. 1021-1025.

Research output: Contribution to journalArticle

Sugarman, Jeremy ; Barker, Roger A. ; Kerridge, Ian ; Lysaght, Tamra ; Pellegrini, Graziella ; Sipp, Douglas ; Tanner, Claire. / Tackling Ethical Challenges of Premature Delivery of Stem Cell-Based Therapies : ISSCR 2018 Annual Meeting Focus Session Report. In: Stem Cell Reports. 2018 ; Vol. 11, No. 5. pp. 1021-1025.
@article{55e055ceaebe48068f58ce307dd9febe,
title = "Tackling Ethical Challenges of Premature Delivery of Stem Cell-Based Therapies: ISSCR 2018 Annual Meeting Focus Session Report",
abstract = "Clinical uses of unproven stem cell-based interventions abound, yet many patients may be harmed by receiving them, raising complex ethical, economic, and societal concerns. Regulators, scientists, clinicians, professional societies, and patient advocacy groups need to collaboratively articulate expectations related to the proper development and delivery of stem cell-based therapies. Clinical uses of unproven stem cell-based interventions abound, yet many patients may be harmed by receiving them, raising complex ethical, economic, and societal concerns. Regulators, scientists, clinicians, professional societies, and patient advocacy groups need to collaboratively articulate expectations related to the proper development and delivery of stem cell-based therapies.",
author = "Jeremy Sugarman and Barker, {Roger A.} and Ian Kerridge and Tamra Lysaght and Graziella Pellegrini and Douglas Sipp and Claire Tanner",
year = "2018",
month = "11",
day = "13",
doi = "10.1016/j.stemcr.2018.10.020",
language = "English (US)",
volume = "11",
pages = "1021--1025",
journal = "Stem Cell Reports",
issn = "2213-6711",
publisher = "Cell Press",
number = "5",

}

TY - JOUR

T1 - Tackling Ethical Challenges of Premature Delivery of Stem Cell-Based Therapies

T2 - ISSCR 2018 Annual Meeting Focus Session Report

AU - Sugarman, Jeremy

AU - Barker, Roger A.

AU - Kerridge, Ian

AU - Lysaght, Tamra

AU - Pellegrini, Graziella

AU - Sipp, Douglas

AU - Tanner, Claire

PY - 2018/11/13

Y1 - 2018/11/13

N2 - Clinical uses of unproven stem cell-based interventions abound, yet many patients may be harmed by receiving them, raising complex ethical, economic, and societal concerns. Regulators, scientists, clinicians, professional societies, and patient advocacy groups need to collaboratively articulate expectations related to the proper development and delivery of stem cell-based therapies. Clinical uses of unproven stem cell-based interventions abound, yet many patients may be harmed by receiving them, raising complex ethical, economic, and societal concerns. Regulators, scientists, clinicians, professional societies, and patient advocacy groups need to collaboratively articulate expectations related to the proper development and delivery of stem cell-based therapies.

AB - Clinical uses of unproven stem cell-based interventions abound, yet many patients may be harmed by receiving them, raising complex ethical, economic, and societal concerns. Regulators, scientists, clinicians, professional societies, and patient advocacy groups need to collaboratively articulate expectations related to the proper development and delivery of stem cell-based therapies. Clinical uses of unproven stem cell-based interventions abound, yet many patients may be harmed by receiving them, raising complex ethical, economic, and societal concerns. Regulators, scientists, clinicians, professional societies, and patient advocacy groups need to collaboratively articulate expectations related to the proper development and delivery of stem cell-based therapies.

UR - http://www.scopus.com/inward/record.url?scp=85055877161&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055877161&partnerID=8YFLogxK

U2 - 10.1016/j.stemcr.2018.10.020

DO - 10.1016/j.stemcr.2018.10.020

M3 - Article

C2 - 30428384

AN - SCOPUS:85055877161

VL - 11

SP - 1021

EP - 1025

JO - Stem Cell Reports

JF - Stem Cell Reports

SN - 2213-6711

IS - 5

ER -